fashion -WSS

fashion

author：Wikipedia 2025-09-06 03:52:54 - browse：1

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Cigna to pay $172 million to settle Medicare Advantage fraud probe

WSS

Would Medicare drug price negotiations stall in a shutdown?

Medicare has a new plan to address drug shortages

Sanders adds drug shortage policies to pandemic preparedness bill

Biden tests positive for Covid

Custom gene therapy hints at new path for rare disease treatments

Menendez indictment could see pharma lose a key ally

entertainment

fashion

leisure time

State Dept. review finds Biden bears some blame for Afghanistan failures

Biogen shutters digital health group, ends Apple study, in cost cutting move

Alkermes shareholders re

As digital health tech proliferates, a new institute aims to cut through hype

At least 13 dead in Texas as scorching temps continue

Medicaid, Medicare dual

Moonlake's readout produced a cash windfall. Risks remain

Data show record exodus of life scientists from academia

Alkermes shareholders re

Doctors find melanoma drugs effective against rare brain cancer

knowledge

Mindstrong's demise and the future of mental health care

STAT Virtual Event: The State of Biosimilars: What to Watch

FDA seeks to regulate lab

Inequities make cancer less preventable for women: report

Key House panel plots a new health care package

Cigna to pay $172 million to settle Medicare Advantage fraud probe

focus

Wikipedia

Wikipedia

leisure time